Repletion of testosterone (Te) in older men drives GH secretion after its aromatization to estradiol (E2), which acts via the estrogen receptor (ER). Conversely, we postulate that estrogen deprivation in postmenopausal women attenuates growth hormone (GH) secretion and insulin-like growth factor-1 (IGF-I) production, thus favoring development of metabolic syndrome in men treated with toremifene, a new estrogen antagonist used adjunctively in prostatic cancer

开始日期2014-12-01

申办/合作机构

Mayo Clinic

100 项与 Truncated somatorelin(Fujisawa Pharmaceutical Co., Ltd.) 相关的临床结果

登录后查看更多信息

100 项与 Truncated somatorelin(Fujisawa Pharmaceutical Co., Ltd.) 相关的转化医学

登录后查看更多信息

100 项与 Truncated somatorelin(Fujisawa Pharmaceutical Co., Ltd.) 相关的专利（医药）

登录后查看更多信息

1,237

项与 Truncated somatorelin(Fujisawa Pharmaceutical Co., Ltd.) 相关的文献（医药）

2024-01-01·Cytokine

Growth hormone-releasing hormone antagonists counteract interferon-γ – induced barrier dysfunction in bovine and human endothelial cells

Article

作者: Barabutis, Nektarios ; Fakir, Saikat

GHRH regulates the secretion of GH from the anterior pituitary gland. An emerging body of evidence suggests that the activities of that neuropeptide are not limited to the GH/IGF-I axis, but they expand towards the mediation of inflammatory processes. GHRHAnt were developed to oppose the activities of GHRH in malignancies, and have been associated with strong anti-inflammatory and anti-oxidative effects in a diverse variety of tissues, including the lungs. In the present study we report that GHRHAnt oppose interferon-γ - induced paracellular hyperpermeability and reactive oxygen species generation in bovine and human pulmonary endothelial cells; and suppress interferon-γ - triggered STAT3, cofilin and ERK1/2 activation. Our observations substantiate previous findings on the protective effects of GHRHAnt in endothelial inflammation and barrier break-down.

2023-12-01·Analytical biochemistry

Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.

Article

作者: David, Victor ; Cristea, Cătălina-Diana ; Radu, Mihai ; Toboc, Ani ; Stan, Cristina

The use of growth hormone-releasing hormones (GHRHs) is prohibited in sports according to the regulations of the World Anti-Doping Agency (WADA). Considering the complexity of urine samples and the low concentrations at which these analytes should be detected, analyzing GHRHs is a challenging task. In most of the studies, GHRHs are analyzed using UHPLC-HRMS with an orbitrap. The present developed and validated method for some GHRHs (tesamorelin, CJC-1295, sermorelin (GRF 1-29), sermorelin (3-29)-NH₂, somatorelin) is based on the triple quadrupole UHPLC/MS-MS method with solid phase extraction (SPE) with weak cation exchange and is able to detect concentrations as low as 0.2 ng/mL (LOD), a limit of quantification (LOQ) at 0.6 ng/mL, and linearity across the range of 0.1 ng/mL to 1.2 ng/mL. The present method developed by our doping control laboratory was validated according to WADA technical documents for selectivity, limit of detection (LOD), carryover, reliability of detection, stability and recovery. The results show that the method has adequate recoveries and sensitivity, hence, it can be employed for routine screening in anti-doping laboratories.

2023-10-01·Journal of endocrinological investigation

GHRH + arginine test and body mass index: do we need to review diagnostic criteria for GH deficiency

Article

作者: Varaldo, E. ; Gasco, V. ; Ghigo, E. ; Bioletto, F. ; Grottoli, S. ; Bona, C. ; Berton, A. M. ; Prencipe, N. ; Maccario, M. ; Cuboni, D.

INTRODUCTIONThe proportion of patients with low GH response to provocative tests increases with the number of other pituitary hormone deficiencies, reason why in panhypopituitary patients GH stimulation tests may be unnecessary to diagnose GH deficiency (GHD) PURPOSE: To re-evaluate the diagnostic cut-offs of GH response to GHRH + arginine (ARG) test related to BMI, considering the patients' pituitary function as the gold standard for the diagnosis of GHD.METHODSThe GH responses to GHRH + ARG were studied in 358 patients with history of hypothalamic-pituitary disease. GHD was defined by the presence of at least 3 other pituitary deficits (n = 223), while a preserved somatotropic function was defined by the lack of other pituitary deficits and an IGF-I SDS ≥ 0 (n = 135). The cut-off with the best sensitivity (SE) and specificity (SP), was identified for each BMI category using the ROC curve analysis. To avoid over-diagnosis of GHD we subsequently searched for the cut-offs with a SP ≥ 95%.RESULTSThe best GH cut-off was 8.0 μg/l (SE 95%, SP 100%) in lean, 7.0 μg/l (SE 97.3%, SP 82.8%) in overweight, and 2.8 μg/l (SE 84.3%, SP 91.7%) in obese subjects. The cut-off with a SP ≥ 95% was 2.6 μg/l (SE 68.5%, SP 96.6%) in overweight and 1.75 μg/l (SE 70.0%, SP 97.2%) in obese subjects.CONCLUSIONSThis is the first study that evaluates the diagnostic cut-offs of GH response to GHRH + ARG related to BMI using a clinical definition of GHD as gold standard. Our results suggest that with this new approach, the GHRH + ARG cut-offs should be revised to avoid GHD over-diagnosis.

100 项与 Truncated somatorelin(Fujisawa Pharmaceutical Co., Ltd.) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Truncated somatorelin(Fujisawa Pharmaceutical Co., Ltd.)	V04CD05	DB12656

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
生长激素缺乏症	临床3期	-	Fujisawa Pharmaceutical Co., Ltd.	-
生长激素缺乏症	临床3期	美国	-	-
生长激素缺乏症	临床3期	-	Bausch Health Americas, Inc.	-
生长激素缺乏症	临床3期	-	Bausch Health Americas, Inc.	-
生长激素缺乏症	临床3期	-	Fujisawa Pharmaceutical Co., Ltd.	-
生长激素缺乏症	临床3期	美国	-	-
肌肉萎缩	临床3期	瑞士	-	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESPE2014	N/A	普拉德-威利综合症 GH peak \| IGF1 levels	28	GHRH+pyridostigmine	築構衊選構鏇鬱範壓築(窪顧鹽繭願廠繭網餘壓) = 簾醖築齋簾獵鏇鑰範遞衊鹽顧顧齋顧廠鏇築鹹 (簾觸製遞積鹹夢鬱鏇鬱 )	-	2014-09-18
Pubmed \| J Clin Endocrinol Metab	N/A	垂体性侏儒症	-	Macimorelin	鏇鹽製廠膚廠壓鏇簾鑰(網築積壓窪蓋廠顧鏇顧) = 窪網衊鏇窪衊遞糧遞廠構構範醖淵範廠鏇艱艱 (衊鏇襯齋糧鑰製簾願鹽 )	-	2013-06-01
Pubmed \| J Clin Endocrinol Metab	N/A	垂体性侏儒症	-	Arginine+GHRH	鏇鹽製廠膚廠壓鏇簾鑰(網築積壓窪蓋廠顧鏇顧) = 鏇積糧鬱鏇蓋鑰鏇鑰廠構構範醖淵範廠鏇艱艱 (衊鏇襯齋糧鑰製簾願鹽 )	-	2013-06-01